Top Stock Picks for the Week

Growth Opportunities in Streaming, Cloud, Healthcare, Infrastructure, and Fintech

As the market continues to navigate uncertainty around trade negotiations, macroeconomic pressures, and inflationary concerns, it’s important to identify companies with strong earnings momentum, solid growth prospects, and attractive valuations. This week, we’re highlighting five companies poised for continued success: Netflix, ServiceNow, Eli Lilly, Vertiv, and Robinhood. These stocks have shown resilience, strong earnings reports, and favorable outlooks. Let’s dive into why each of these stocks stands out this week.

Netflix (NFLX)

Current Earnings and Stock Performance:
Netflix reported strong Q1 2025 earnings with revenue of $9.37 billion, marking a 13% year-over-year increase, and earnings per share (EPS) of $6.61, up 25% from the previous year. The company’s content strategy remains a key driver of growth, with several of its new releases performing exceptionally well. Despite some market volatility, Netflix’s stock has held its ground, driven by its leadership in global streaming and strong cash flow generation.

Guidance and Valuation:
Netflix’s forward guidance for Q2 indicates continued strong performance, with expectations for revenue growth of 12-14% year-over-year. The company is also well-positioned to grow its advertising revenue, contributing to its diversified income streams. Netflix trades at a forward P/E ratio of 41.4x, slightly above its historical average but still attractive given its growth prospects and high margins.

Here's Our Take:
Netflix continues to dominate the streaming space with impressive growth in its content library and expanding advertising business. The company’s ability to balance subscription growth with ad revenue in a maturing market makes it a compelling choice. With strong free cash flow and a solid content pipeline, Netflix is poised to continue its leadership in the entertainment sector, making it an attractive pick for growth investors.

ServiceNow (NOW)

Current Earnings and Stock Performance:
ServiceNow reported Q1 2025 earnings of $4.04 per share, exceeding consensus estimates. Revenue grew 18.5% year-over-year to $3.09 billion, driven by strong demand for its cloud-based solutions that automate enterprise workflows. The stock has been trading near all-time highs, reflecting its strong performance and growth potential.

Guidance and Valuation:
ServiceNow raised its full-year 2025 guidance, expecting Subscription revenue to grow between 18.5-19% year-over-year. The company is benefiting from the continued shift to cloud solutions, and its revenue guidance reflects ongoing strength in demand. ServiceNow trades at a premium with a forward P/E of 54.5x, but its high-growth nature and strong market position justify the valuation for long-term investors.

Here's Our Take:
ServiceNow’s leadership in cloud-based workflow automation continues to set it apart in the enterprise software market. The company’s ability to drive strong revenue growth through its platform's adoption positions it well for continued expansion in the cloud space. Despite the high valuation, ServiceNow’s market position, strong customer base, and long-term growth outlook make it a compelling choice for investors seeking exposure to the digital transformation trend.

Eli Lilly (LLY)

Current Earnings and Stock Performance:
Eli Lilly’s Q1 2025 earnings came in at $3.34 per share, a 25% year-over-year increase. Revenue surged 45% to $12.73 billion, driven by strong sales of its diabetes and obesity treatments, Mounjaro and Zepbound. These incretin-based therapies are leading the market and showing impressive uptake across global markets. Eli Lilly’s stock has been one of the top performers in the healthcare sector, reflecting investor confidence in its growth prospects.

Guidance and Valuation:
Eli Lilly has reaffirmed its 2025 revenue guidance of $58–61 billion and increased its EPS guidance to $20.78–22.28, reflecting continued strength in its core therapeutic areas. The stock is currently trading at a forward P/E of 31.4x, below to its historical 5 year average of 35.7x. While its multiple far exceeds pharma peers like Novo Nordisk (~15.8x), Merck (~8.6x), and Pfizer (~7.5x), we still believe it is justified by its leadership in the incretin space and robust pipeline of new therapies.

Here's Our Take:
Eli Lilly’s continued dominance in the incretin-based therapy market, driven by Mounjaro and Zepbound, positions the company for strong growth. The pipeline remains robust, and the company’s strategic focus on diabetes and obesity treatments offers significant long-term growth potential. Last month, the company announced that it had achieved a major milestone in the treatment of type 2 diabetes, marking the first successful oral GLP-1 receptor agonist to complete Phase 3 trials. Despite its rich valuation, Eli Lilly’s solid fundamentals and innovation-driven growth make it a top pick for long-term investors in the healthcare sector.

Vertiv (VRT)

Current Earnings and Stock Performance:
Vertiv delivered a solid Q1 2025 with revenue growth of 24.2% year-over-year to $2.0 billion. The company’s product offerings in data center infrastructure continue to benefit from the increasing digitalization of businesses. Vertiv’s stock has shown resilience, reflecting both the strong demand for its products and its leading position in the data center market.

Guidance and Valuation:
Vertiv raised its full-year guidance, expecting revenue to grow in the mid-single digits. The company’s continued investments in data center infrastructure are expected to drive further demand in 2025 and beyond. Vertiv’s forward P/E ratio is 24.4x, slightly above its 5-year average, but still offers a reasonable valuation for investors seeking exposure to the growing digital infrastructure space.

Here's Our Take:
Vertiv is a key player in the rapidly expanding data center infrastructure market. As businesses continue to invest in digitalization and cloud computing, Vertiv’s solutions are critical for maintaining the efficiency and reliability of data centers. With a strong balance sheet, solid growth outlook, and attractive valuation, Vertiv is well-positioned to capitalize on the increasing demand for digital infrastructure.

Robinhood (HOOD)

Current Earnings and Stock Performance:
Robinhood reported Q1 2025 earnings of $0.37 per share, beating estimates. Revenue grew 50% year-over-year to $927 million, driven by an increase in user activity and higher asset balances. Robinhood’s stock has gained 41.2% over the last month, reflecting improved investor sentiment and stronger financial performance, particularly from its crypto and options trading businesses.

Guidance and Valuation:
Robinhood’s forward guidance for Q2 suggests continued growth, particularly in its crypto business, which has benefitted from increased interest in digital currencies. The company’s efforts to diversify its revenue streams, including its growing advisory business, position it for sustained success. Robinhood’s stock currently trades at a forward P/E of 34.7x, attractive for investors looking for exposure to a leader in the fintech space.

Here's Our Take:
Robinhood’s strong Q1 results highlight its ability to capture market share in the growing fintech sector. With a strong balance sheet, growing user base, and increasing demand for its trading and crypto platforms, Robinhood is well-positioned to maintain its momentum. Despite the volatility in the markets, Robinhood's diversification strategy and improving profitability make it a solid pick for investors seeking exposure to the fintech space.

These five stocks - Netflix, ServiceNow, Eli Lilly, Vertiv, and Robinhood - offer strong growth prospects and attractive valuations. From Netflix’s content and advertising dominance to ServiceNow’s position as a cloud software leader, Eli Lilly’s growth in the healthcare sector, Vertiv’s role in digital infrastructure, and Robinhood’s fintech expansion, each of these companies is poised for success. Whether you’re looking for growth in entertainment, software, healthcare, infrastructure, or fintech, these stocks stand out as strong picks for long-term capital appreciation.

P.S. Know someone who'd appreciate smarter stock insights and clearer investing strategies? Forward this email or share this link: subscribe.triplegains.com